|Articles|June 27, 2011
Linagliptin cardiovascular safety profile appears superior to glimepiride
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.
Advertisement
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Medical Economics
1
UPDATE: CMS now says most payments to physicians will be paid 'in a timely manner' as government shutdown continues
2
Unpacking Medicare’s $15B skin substitute boom, with HHS-OIG Regional Inspector General David Tawes, M.A.
3
How smart practices are turning text messages into revenue
4
Trump threatens to upend GLP-1 market with vow to slash Ozempic prices
5